Donepezil/solifenacin

Drug Profile

Donepezil/solifenacin

Alternative Names: Cognicept; CPC-201

Latest Information Update: 07 Dec 2016

Price : $50

At a glance

  • Originator Chase Pharmaceuticals
  • Class Antidementias; Antispasmodics; Esters; Indans; Isoquinolines; Nootropics; Piperidines; Quinuclidines; Small molecules
  • Mechanism of Action Acetylcholinesterase inhibitors; Cholinergic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Alzheimer's disease; Dementia

Most Recent Events

  • 22 Nov 2016 Chase Pharmaceuticals has been acquired by Allergan
  • 08 Aug 2016 Chase Pharmaceuticals plans a phase II study for Dementia of Alzheimer's type in USA (NCT02860065)
  • 27 Jul 2016 Efficacy and adverse events data from a phase II trial in Alzheimer’s disease presented at the Alzheimer’s Association Conference (AAIC-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top